SCHEMBL13253129

SCHEMBL13253129

NCC(c1ccccc1)c1c[nH]c2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.74
KMT2A Q03164 5/20 0.74
MAPT P10636 2/20 0.74
USP2 O75604 1/20 0.74
ALDH1A1 P00352 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
HTR2A P28223 2/20 0.63
HTR2C P28335 1/20 0.63
HTR2B P41595 1/20 0.63
GPR84 Q9NQS5 3/20 0.62
CYP2D6 P10635 1/20 0.61
SLC6A2 P23975 1/20 0.61
SLC6A4 P31645 1/20 0.61
KCNH2 Q12809 1/20 0.61
MGAM O43451 5/20 0.60
GAA P10253 5/20 0.60
SI P14410 5/20 0.60
MGAM2 Q2M2H8 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823826 0.91 MEN1 (0.70) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL7015690 0.89 MEN1 (0.73) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL2073813 0.87 CYP2D6 (0.67) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL7011743 0.85 MEN1 (0.64) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL7006159 0.85 NR3C1 (0.69) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL2074209 0.85 HTR2A (0.61) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL14168804 0.84 GPR84 (0.64) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL1348944 0.83 MGAM (0.64) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL7967556 0.83 GPR84 (0.62) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL27682946 0.83 GPR84 (0.62) MEN1KMT2AMAPTUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100189648-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF HUANG LAN 2010-07-29 US disclosed
US-20100189648-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF HUANG LAN 2010-07-29 US disclosed
WO-2008052441-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF HUANG LAN (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189648-A1 INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF MDM2, UBE2N, UBE2E1 MEN1 3921/4885KMT2A 795/4885MAPT 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.